# Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

> **NCT01751165** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 354 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Herpes zoster vaccine GSK1437173A

## Key facts

- **NCT ID:** NCT01751165
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-12
- **Primary completion:** 2014-05-22
- **Final completion:** 2015-04-08
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01751165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01751165, "Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01751165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*